POM-V Prescription Required Companion Animal

Onsior 20 mg/ml Solution for Injection for Cats and Dogs

Active ingredient: Robenacoxib

Form

Injection

Species

Cats Dogs

Manufacturer

Elanco GmbH

VMD MA No.

52127/5021

What it's used for

For the treatment of pain and inflammation associated with orthopaedic or soft tissue surgery in dogs. For the treatment of pain and inflammation associate...

Full indications, dosage and side effects ↓

View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Robenacoxib

1

Ask your vet for a written prescription

They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
2

Fill it at a registered online retailer

The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Your prescription rights → VMD register of retailers →

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Onsior 20 mg/ml Solution for Injection for Cats and Dogs — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 26 Mar 2026.

For the treatment of pain and inflammation associated with orthopaedic or soft
tissue surgery in dogs.
For the treatment of pain and inflammation associated with orthopaedic or soft
tissue surgery in cats.

Do not use in animals suffering from gastrointestinal ulceration.
Do not use concomitantly with corticosteroids or other non-steroidal anti-
inflammatory drugs (NSAIDs).

Issued: October 2023
AN: 02941/2022
Do not use in case of hypersensitivity to the active substance or to any of the
excipients.
Do not use in pregnant and lactating animals (see section 4.7).

Cats:
Common
(1 to 10 animals / 100 animals
treated):
Injection site pain
Digestive tract disorder
, Diarrhoea
, Vomiting
Uncommon
(1 to 10 animals / 1000 animals
treated):
Bloody diarrhoea, Blood in vomit
Most cases were mild and recovered without treatment.
Dogs:
Common
(1 to 10 animals / 100 animals
treated):
Injection site pain
Digestive tract disorder
, Diarrhoea
, Vomiting
Uncommon
(1 to 10 animals / 1000 animals
treated):
Tarry stool
Decreased appetite
Moderate or severe pain at injection site was uncommon
Most cases were mild and recovered without treatment.
Reporting adverse events is important. It allows continuous safety monitoring of
a veterinary medicinal product. Reports should be sent, preferably via a
veterinarian, to either the marketing authorisation holder or its local
representative or the national competent authority via the national reporting
system. See also the last section of the package leaflet for contact details.

None.

i). Special precautions for use in animals
The safety of the veterinary medicinal product has not been established in cats
less than 4 months of age and in dogs less than 2 months of age, or in cats or
dogs less than 2.5 kg body weight.
Use in animals with impaired cardiac, renal or hepatic function or those are
dehydrated, hypovolaemic or hypotensive may involve additional risks. If use
cannot be avoided, these animals require careful monitoring and fluid therapy.
Use this veterinary medicinal product under strict veterinary monitoring in cases
at risk of gastrointestinal ulceration, or if the animal previously displayed
intolerance to other NSAIDs.
ii). Special precautions to be take by the person administering the veterinary
medicinal product to animals
Wash hands and exposed skin immediately after use of the product.
In case of accidental ingestion or self-injection, seek medical advice
immediately and show the package leaflet or the label to the physician.
For pregnant women, particularly near-term pregnant women, accidental
injection and prolonged dermal exposure increases the risk for premature
closure of the ductus arteriosus in the foetus.
Special precautions for the protection of the environment:
Not applicable.
iii). Other precautions
Not applicable.

Issued: October 2023
AN: 02941/2022

This veterinary medicinal product must not be administered in conjunction with
other NSAIDs or glucocorticosteroids. Pre-treatment with other anti-
inflammatory medicines may result in additional or increased adverse effects
and accordingly a treatment-free period with such substances should be
observed for at least 24 hours before the commencement of treatment with this

Issued: October 2023
AN: 02941/2022
veterinary medicinal product. The treatment-free period, however, should take
into account the pharmacokinetic properties of the products used previously.
Concomitant treatment with medicines displaying action on renal flow, e.g.
diuretics or angiotensin-converting enzyme (ACE) inhibitors, should be subject
to clinical monitoring.
In healthy cats or dogs treated with or without the diuretic furosemide,
concomitant administration of this veterinary medicinal product with the ACE
inhibitor benazepril for 7 days was not associated with any negative effects on
plasma (cats) or urine (dogs) aldosterone concentrations, plasma renin activity
or glomerular filtration rate. No safety data in the target population and no
efficacy data in general exist for the combined treatment of robenacoxib and
benazepril.
As anaesthetics may affect renal perfusion, the use of parenteral fluid therapy
during surgery should be considered to decrease potential renal complications
when using NSAIDs peri-operatively.
Concurrent administration of potentially nephrotoxic medicines should be
avoided as there might be an increased risk of renal toxicity.
Concurrent use of other active substances that have a high degree of protein
binding may compete with robenacoxib for binding and thus lead to toxic
effects.

Store in a refrigerator (2 °C – 8 °C). Refrigeration is not required during the 4-week
in-use period after first broaching of the vial. Avoid introduction of contamination.
Keep the vial in the outer carton.

Not applicable.
5.

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.